Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

NEJM ESSENCE trial Phase 3 results announced. Semaglutide can resolve MASH. Male doctor speaking with overweight female patient in an exam room.

🚨NEW IN #NEJM🚨ESSENCE #VCU-led researchers report weekly injections of #semaglutide resolved steatohepatitis without worsening of fibrosis in 63% of #MASH patients getting weekly semaglutide injections, across 37 countries. #liver www.nejm.org/doi/full/10....

30.04.2025 21:04 — 👍 1    🔁 0    💬 0    📌 0

Screening for MASLD by at 29th Annual Virginia Liver Symposium by @juanpabloarab.bsky.social @vculiver.bsky.social

🌎 prevalence of MASLD 30%
⬆️ risk progression with DM, HTN, obesity, menopause
Screen for 🍷
♻️ Putative connection between MASLD, CVD, CKD

26.04.2025 19:11 — 👍 0    🔁 1    💬 0    📌 0

Team VCU at AASLD MASLD/MetALD/ALD Emerging Topic Conference 2025, Las Vegas

@juanpabloarab.bsky.social @saulkarpen.bsky.social @vculiver.bsky.social

02.03.2025 17:46 — 👍 5    🔁 2    💬 0    📌 1

Thanks #CDDW #CLM Chris Rose & Premsyl Bercik for the invite to speak in a beautiful but freezing Quebec city on #HE #microbes & #gutbrainaxis. Excellent joint session with #microbiology & #gi expertise. 🇨🇦 warmth shone thru despite the polar vortex!! @vculiver.bsky.social

02.03.2025 14:30 — 👍 8    🔁 2    💬 2    📌 0

Thrilled that we're represented!

03.03.2025 14:53 — 👍 0    🔁 0    💬 0    📌 0

JCI Insight - Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with FMT Research LetterIn-Press PreviewHepatologyMicrobiology Open Access | 10.1172/jci.insight.186649

ASCI member Jasmohan S. Bajaj @jasmohanbajaj et al. @VCU_liver show that fecal transplant ameliorates a source of cirrhosis progression:

27.02.2025 18:38 — 👍 0    🔁 1    💬 0    📌 0

🙏 @paulsaxmd.bsky.social for the invitation to write this from a #liversky and #IDsky perspective @cidjournal.bsky.social
Totally agree the approach needs to shift! @vculiver.bsky.social @idsainfo.bsky.social @easlnews.bsky.social @varesearch.bsky.social

05.02.2025 13:43 — 👍 14    🔁 4    💬 1    📌 0

🙏 for highlighting our commentary @cidjournal.bsky.social
Need to re-evaluate these practices due to ⬆️
- #amr burden
- C difficile & #antibiotic adverse events
- costs
#liversky #gisky @varesearch.bsky.social @idsainfo.bsky.social @amcollegegastro.bsky.social @easlnews.bsky.social

03.02.2025 15:53 — 👍 6    🔁 4    💬 0    📌 0

Check out @nytimes.com interview of experts re: #wellness my tip? Coffee for the win!! Liver brain and microbes all benefit from this
Check it out below
www.nytimes.com/interactive/... @vculiver.bsky.social @amcollegegastro.bsky.social @ebtapper.bsky.social @easlnews.bsky.social

13.01.2025 16:01 — 👍 16    🔁 7    💬 0    📌 1

FDA Issues Safety Alert on Liver Disease Drug Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis

Gastroenterology>General Hepatology

FDA Issues Safety Alert on Liver Disease Drug.
— Obeticholic acid (Ocaliva) may cause serious liver damage even in PBC patients without cirrhosis.

by Ian Ingram, Managing Editor, MedPage Today www.medpagetoday.com/gastroentero...

14.12.2024 07:37 — 👍 3    🔁 1    💬 0    📌 0

Attendees at the year-end party for the VCU Division of GI, Hep, & Nutrition and the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.

Taking a first step on Bsky ... here's our team and colleagues at #VCU's Division of GI, Hep and Nutrition. #liversky #gastrosky

16.12.2024 16:05 — 👍 9    🔁 0    💬 0    📌 0